Martina Manzoni

Dr. Martina Manzoni

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2018 in Blood
Verified
Journal Article
Closed access
PDF file
VSValeria Spina
Valeria Spina
ABAlessio Bruscaggin
Alessio Bruscaggin
ACAnnarosa Cuccaro
Annarosa Cuccaro
MMMaurizio Martini
Maurizio Martini
MTMartina Di Trani
Martina Di Trani
DRDavide Rossi
Davide Rossi
The rarity of neoplastic cells in the biopsy imposes major technical hurdles that have so far limited genomic studies in classical Hodgkin lymphoma (cHL). By using a highly sensitive and robust deep next-generation sequencing approach for circulating tumor DNA (ctDNA), we aimed to identify the genetics of cHL in different clinical phases, as well as its modifications on treatment. The analysis was based on specimens collected from 80 newly diagnosed and 32 refractory patients with cHL, including longitudinal samples collected under ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy and longitudinal samples from relapsing patients treated with chemotherapy and immunotherapy. ctDNA mirrored Hodgkin and Reed-Sternberg cell genetics, thus establishing ctDNA as an easily accessible source of tumor DNA for cHL genotyping. By identifying STAT6 as the most frequently mutated gene in ∼40% of cases, we refined the current knowledge of cHL genetics. Longitudinal ctDNA profiling identified treatment-dependent patterns of clonal evolution in patients relapsing after chemotherapy and patients maintained in partial remission under immunotherapy. By measuring ctDNA changes during therapy, we propose ctDNA as a radiation-free tool to track residual disease that may integrate positron emission tomography imaging for the early identification of chemorefractory patients with cHL. Collectively, our results provide the proof of concept that ctDNA may serve as a novel precision medicine biomarker in cHL. Publisher9s Note: There is a Blood Commentary on this article in this issue. Key Points ctDNA is as an easily accessible source of tumor DNA for cHL genotyping. ctDNA is a radiation-free tool to track residual disease in cHL. Visual Abstract

22 February 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
NANicola Amodio
Nicola Amodio
MSMaria Angelica Stamato
Maria Angelica Stamato
GJGiada Juli
Giada Juli
EMEugenio Morelli
Eugenio Morelli
MFMariateresa Fulciniti
Mariateresa Fulciniti
PTPierfrancesco Tassone
Pierfrancesco Tassone
The biological role and therapeutic potential of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) are still to be investigated. Here, we studied the functional significance and the druggability of the oncogenic lncRNA MALAT1 in MM. Targeting MALAT1 by novel LNA-gapmeR antisense oligonucleotide antagonized MM cell proliferation and triggered apoptosis both in vitro and in vivo in a murine xenograft model of human MM. Of note, antagonism of MALAT1 downmodulated the two major transcriptional activators of proteasome subunit genes, namely NRF1 and NRF2, and resulted in reduced trypsin, chymotrypsin and caspase-like proteasome activities and in accumulation of polyubiquitinated proteins. NRF1 and NRF2 decrease upon MALAT1 targeting was due to transcriptional activation of their negative regulator KEAP1, and resulted in reduced expression of anti-oxidant genes and increased ROS levels. In turn, NRF1 promoted MALAT1 expression thus establishing a positive feedback loop. Our findings demonstrate a crucial role of MALAT1 in the regulation of the proteasome machinery, and provide proof-of-concept that its targeting is a novel powerful option for the treatment of MM.

19 August 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
ETElisa Taiana
Elisa Taiana
VFVanessa Favasuli
Vanessa Favasuli
DRDomenica Ronchetti
Domenica Ronchetti
KTKatia Todoerti
Katia Todoerti
FPFrancesca Pelizzoni
Francesca Pelizzoni
Antonino NeriAntonino Neri
Antonino Neri

22 July 2022 in Circulation Research
Verified
Journal Article
Closed access
PDF file
GGGloria Garoffolo
Gloria Garoffolo
MCManuel Casaburo
Manuel Casaburo
FAFrancesco Amadeo
Francesco Amadeo
Massimo SalviMassimo Salvi
Massimo Salvi
GBGiacomo Bernava
Giacomo Bernava
Maurizio PesceMaurizio Pesce
Maurizio Pesce
Background: Conversion of cardiac stromal cells into myofibroblasts is typically associated with hypoxia conditions, metabolic insults, and/or inflammation, all of which are predisposing factors to cardiac fibrosis and heart failure. We hypothesized that this conversion could be also mediated by response of these cells to mechanical cues through activation of the Hippo transcriptional pathway. The objective of the present study was to assess the role of cellular/nuclear straining forces acting in myofibroblast differentiation of cardiac stromal cells under the control of YAP (yes-associated protein) transcription factor and to validate this finding using a pharmacological agent that interferes with the interactions of the YAP/TAZ (transcriptional coactivator with PDZ-binding motif) complex with their cognate transcription factors TEADs (TEA domain transcription factors), under high-strain and profibrotic stimulation. Methods: We employed high content imaging, 2-dimensional/3-dimensional culture, atomic force microscopy mapping, and molecular methods to prove the role of cell/nuclear straining in YAP-dependent fibrotic programming in a mouse model of ischemia-dependent cardiac fibrosis and in human-derived primitive cardiac stromal cells. We also tested treatment of cells with Verteporfin, a drug known to prevent the association of the YAP/TAZ complex with their cognate transcription factors TEADs. Results: Our experiments suggested that pharmacologically targeting the YAP-dependent pathway overrides the profibrotic activation of cardiac stromal cells by mechanical cues in vitro, and that this occurs even in the presence of profibrotic signaling mediated by TGF-β1 (transforming growth factor beta-1). In vivo administration of Verteporfin in mice with permanent cardiac ischemia reduced significantly fibrosis and morphometric remodeling but did not improve cardiac performance. Conclusions: Our study indicates that preventing molecular translation of mechanical cues in cardiac stromal cells reduces the impact of cardiac maladaptive remodeling with a positive effect on fibrosis.

17 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DRDomenica Ronchetti
Domenica Ronchetti
Luca AgnelliLuca Agnelli
Luca Agnelli
ETElisa Taiana
Elisa Taiana
SGSerena Galletti
Serena Galletti
MMMartina Manzoni
Martina Manzoni
Antonino NeriAntonino Neri
Antonino Neri
Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma

6 September 2018 in Blood
Verified
Journal Article
Closed access
PDF file
EMEugenio Morelli
Eugenio Morelli
LBLavinia Biamonte
Lavinia Biamonte
CFCinzia Federico
Cinzia Federico
NANicola Amodio
Nicola Amodio
Maria Di MartinoMaria Di Martino
Maria Di Martino
PTPierfrancesco Tassone
Pierfrancesco Tassone
The microRNA (miRNA) cluster miR-17-92 is oncogenic and represents a valuable therapeutic target in c-MYC (MYC)–driven malignancies. Here, we developed novel LNA gapmeR antisense oligonucleotides (ASOs) to induce ribonuclease H–mediated degradation of MIR17HG primary transcripts and consequently prevent biogenesis of miR-17-92 miRNAs (miR-17-92s). The leading LNA ASO, MIR17PTi, impaired proliferation of several cancer cell lines (n = 48) established from both solid and hematologic tumors by on-target antisense activity, more effectively as compared with miR-17-92 inhibitors. By focusing on multiple myeloma (MM), we found that MIR17PTi triggers apoptosis via impairment of homeostatic MYC/miR-17-92 feed-forward loops (FFLs) in patient-derived MM cells and induces MYC-dependent synthetic lethality. We show that alteration of a BIM-centered FFL is instrumental for MIR17PTi to induce cytotoxicity in MM cells. MIR17PTi exerts strong in vivo antitumor activity in nonobese diabetic severe combined immunodeficient mice bearing clinically relevant models of MM, with advantageous safety and pharmacokinetic profiles in nonhuman primates. Altogether, MIR17PTi is a novel pharmacological tool to be tested in early-phase clinical trials against MM and other MYC-driven malignancies. Publisher9s Note: There is a Blood Commentary on this article in this issue. Key Points First-in-class MIR17PTi enables 1-shot downregulation of miR-17-92 in vitro and in vivo, with favorable pharmacokinetic profile. MIR17PTi affects homeostatic MYC/miR-17-92 FFLs in MM cells, resulting in strong anti-MM activity. Visual Abstract